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1. Introduction 
Continuous administration of the drugs included under the term Highly Active 
Antiretroviral Therapy (HAART) has turned AIDS into a chronic disease, at least in 
developed countries (Panos et al., 2008). The initial development of these drugs was 
particularly rapid and focused on clinical efficacy before all other considerations. However, 
as the disease has come under control, there has been growing emphasis on the long-term 
adverse effects associated with this therapy. 
The first drug for the treatment of HIV infection, zidovudine (AZT), was approved in 1987. 
The number of other antiretroviral drugs already approved for use or under development 
continues to grow, and the primary aim of researchers in the field is to improve their 
efficacy, safety and tolerability. Currently, there are 25 licensed antiretroviral drugs that 
belong to 6 different families: eight nucleoside (nucleotide) reverse transcriptase inhibitors 
(N[t]RTI) which inhibit competitively the viral reverse transcriptase, four non-nucleoside 
reverse transcriptase inhibitors (NNRTI), which produce a direct inhibition of the reverse 
transcriptase and a reduction in its catalytic activity, ten protease inhibitors (PI), which 
inactivate the HIV protease and prevent the generation of new viruses capable of infecting 
other cells, one fusion inhibitor, which prevents the fusion of the virus envelope with the 
host-cell membrane, one CCR5 inhibitor, which blocks the interaction of the virus with one 
of its receptors on the host cell, and, finally, one integrase inhibitor, whose function is to 
block viral DNA integration in the nuclear genome. 
HAART aims to slow the rate of viral replication to the point of reducing the viral load and 
producing a significant immune system reconstitution that increases circulating levels of 
CD4+ T cells. HAART usually combines the three major families of drugs: nucleoside reverse 
transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease 
inhibitors. According to current guidelines, HAART regimens for initial treatment consist of 
two N(t)RTI plus either a NNRTI or a boosted PI (Hammer et al., 2008). NNRTI-based 
regimens have been in use for over a decade now, with the NNRTI of choice being 
Nevirapine (NVP) (for first line therapy in countries with limited resources) and Efavirenz 
(EFV) (for the treatment of naïve patients). Although considered to be safe and well-
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tolerated drugs, their low genetic barrier against the development of resistance and new and 
growing evidence of potential long-term toxicity associated with their use has generated a 
need for new improved drugs in this class. One new arrival is etravirine, which has already 
been approved by the Food and Drug Administration (FDA), and there are currently four 
other compounds in different stages of clinical development (rilpivirine, RDEA806, IDX899 
and lersivirine).  
 
 
Fig. 1. Currently employed antiretroviral drugs and clinical guidelines in the treatment of 
HIV infection. The approved compounds are listed for each family.  
2. NNRTI 
This family is composed of highly specific inhibitors of HIV-1 characterized by a long-
plasmatic half-life that allows once-daily dosing. Although all NNRTI have heterogenic 
chemical structures, they reduce HIV-1 replication through the same mechanism, which 
consists of non-competitive inhibition of the viral reverse transcriptase through binding to a 
hydrophobic pocket located close to the enzyme’s catalytic site and inducing conformational 
changes that affect the catalytic activities of the enzyme (Sluis-Cremer, 2004). It is important 
to note that NNRTI are biotransformed in the liver via the cytochrome P450 pathway, which 
means there is potential for interactions with other drugs whose metabolism uses the same 
pathway. 
The first member of this family to be approved by the FDA was NVP, in 1996, followed by 
Delavirdine (DLV) in 1997 and EFV in 1998. Nowadays, the NNRTIs of choice are NVP and 
EFV, which are still essential components of first-line HAART. On the other hand, DLV is no 
longer used due to its limited efficacy. First generation NNRTI exhibit a somewhat 
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ineffective genetic barrier to the development of resistance, and have been shown to induce 
several moderate-to-severe side effects whose frequency and severity vary significantly with 
each compound, including hepatotoxicity, cutaneous reactions, central nervous system 
toxicity, metabolic alterations and gastrointestinal adverse events (van den Berg-Wolf, 2008; 
Jena, 2009). These disadvantages have fuelled the search of new NNRTI with an improved 
resistance profile and higher efficacy and tolerability, such as Etravirine (ETR), which was 
approved by the FDA in 2008 (Martínez, 2010). The chemical structures of the NNRTI 
currently available and in clinical development are shown in Figure 2. 
 
 
Fig. 2. Chemical structures of approved NNRTI (nevirapine, delavirdine, efavirenz and 
etravirine) and NNRTI in clinical development (rilpivirine, RDEA806, IDX899 and 
lersivirine.  
2.1 Nevirapine 
This NNRTI is recommended for first line therapy in resource-limited countries, but, due to 
its low teratogenesis and paediatric toxicity, it is also widely employed in pregnant women 
and young children in the developed world. This dipyridodiazepinone is usually 
administered in twice-daily doses of 200mg, achieving peak plasma concentrations (2 ± 
0.4g/ml) at 4h. However, several clinical trials have also shown it to be safe and effective in 
a once-daily regimen of 400mg (Garcia, 2000; van Leth, 2004). Despite no major differences 
being reported between these two regimens, once-daily dosing has been shown to produce 
complications, including lower minimum concentration (Cmin) and higher maximum 
concentration (Cmax) levels and a high risk of rash, which can be minimized  by generating 
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tolerance through the administration of a twice-daily dose for a few weeks prior to 
treatment (Cooper, 2007). This compound is biotransformed via cytochrome P450 
isoenzymes, mainly from the CYP3A family, into several hydroxylated metabolites, and its 
plasma half-life ranges from 45h (with a single dose) to 25 - 30h (with repetitive dosing) 
(Cooper, 2007). The most frequently described adverse effects of NVP are rash and 
hepatotoxicity. 
2.2 Delavirdine 
Regulatory agencies have advised against the use of DLV in initial therapy, and so current 
regimens rarely contain this bis(hetero-aryl)piperazine, as it is less effective than other 
NNRTI, is accompanied by complex drug interactions and requires a more inconvenient 
administration. It is characterized by a rapid absorption following oral administration, with 
peak plasma concentrations occurring approximately 1 hour after dosing. The 
recommended dosage of DLV is 400mg three times per day, which results in a Cmax of 
35 ± 20M and a Cmin of 15 ± 10M, and a mean half-life of 5.8h. CYP3A isoenzymes of the 
cytochrome P450 system are the main effectors of DLV conversion into several inactive 
metabolites, although in vitro data also suggest the involvement of CYP2D6. The major 
manifestation of its toxicity is rash (Rescriptor official FDA information, 2011).  
2.3 Efavirenz 
EFV, combined with two NRTI, is the recommended option for initial therapy and is the 
most widely used NNRTI. This benzoxazinone has a long half-life (at least 52h with single 
doses and 40 - 55h with multiple doses), which makes it suitable for once-daily dosing, with 
600mg being the recommended dose for adults. Peak EFV plasma concentrations are 
reached 3 - 5h after a single oral dose and become steady at 6 - 7 days (Maggiolo, 2009). An 
important pharmacokinetic inter-individual variability has been reported in patients taking 
EFV: a daily dose of 600mg usually results in a Cmax of 12.9 ± 3.7M and a Cmin of 5.6 ± 
3.2M (Starr, 1999; Staszewski, 1999), but higher levels (between 30 - 50M) have been 
observed in as many as 20% of patients (Marzolini, 2001; Burguer, 2006).  
This drug is extensively biotransformed into inactive hydroxylated metabolites via the 
cytochrome P450 system, and CYP2B6 is likely to be the corresponding isoenzyme. 
Moreover, in vitro studies suggest that the wide inter-individual variability in the expression 
and activity of CYP2B6, in addition to its genetic polymorphisms, could lie behind the 
variability in EFV pharmacokinetics (Ward, 2003). It is also important to note that EFV levels 
can vary if it is co-administered with other drugs that influence this isoenzyme. Despite its 
apparent safety, several adverse events of EFV-containing therapies have emerged, such as 
rash, neuropsychiatric disturbances, lipid and metabolic alterations, and hepatotoxicity 
(Maggiolo, 2009).   
2.4 Etravirine 
The most recent approved NNRTI is a di-aryl-pyrimidine. It has shown sustained clinical 
efficacy in HIV-1 strains that are resistant to other compounds of the same family and has a 
higher genetic barrier to the development of resistance than older NNRTI. ETR is less 
susceptible to drug-resistant mutations, probably due to the fact that it binds to the reverse 
transcriptase in multiple conformations (Dickinson, 2010; Martínez, 2010). Although several 
recent trials suggest that its long half-life (30 - 40h) makes it suitable for once-daily dosing 
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(400mg), the current recommended dosage for ETR is 200mg twice daily, which results in a 
Cmax of 0.79 - 0.80g/ml 4h after administration. As with other NNRTI, its metabolism 
depends on several isoforms of the cytochrome P450, primarily CYP3A4, CYP2C9 and 
CYP2C19. Thus, its use in combination with other drugs that also induce the cytochrome 
P450 is not recommended. Existing clinical evidence shows that ETR is well tolerated in 
patients, with low rates of discontinuation as a result of detrimental effects. In the PhaseIII 
trials DUET-1 and DUET-2, the primary adverse effect associated with ETR was mild-to-
moderate rash, and no association was found with hepatic/lipid abnormalities or with a 
higher incidence of psychiatric disorders (Lazzarin, 2007; Madruga, 2007; Schiller, 2009). 
However, data about ETR are still limited due to its recent commercialisation, and further 
clinical and in vitro analyses are needed in order to determine the full side effects of this 
compound. 
2.5 NNRTI in clinical development 
New NNRTI are currently being developed as part of the quest to find efficient compounds 
with greater resistance and a lower frequency of adverse effects. The information available 
about the clinical relevance and pharmacokinetic and toxicological profiles of the four 
NNRTI currently under clinical development is limited, which makes it difficult to predict 
their potential as therapy for HIV infection. Nevertheless, several ongoing trials are 
investigating the efficacy, safety and tolerability of these drugs. 
2.5.1 Rilpivirine (TMC278)  
The pharmacokinetics of this di-aryl-pyrimidine compound allow once-daily dosing, 
usually with 25mg, and its good bioavailability makes it a potential candidate for co-
formulation. In fact, studies are underway to develop a new once-daily fixed-dose 
antiretroviral regimen containing Emtricitabine, Tenofovir disoproxil fumarate and 
Rilpivirine hydrochloride (de Béthune, 2010). Rilpivirine has an in vitro resistance profile 
comparable to that of ETR (Azijn, 2010), and results from week 96 of a Phase IIB trial 
(TMC278-C204) in naïve patients have demonstrated a potent and sustained efficacy similar 
to that of EFV, while it seems to produce fewer adverse events. Indeed, rilpivirine is 
associated with fewer incidences of neuropsychiatric events and rash, and a smaller rise in 
lipid levels than EFV (Pozniak, 2010).  
2.5.2 RDEA806 
In vitro studies have reported that this triazole compound exerts a potent activity against 
both wild-type and NNRTI-resistant HIV-1 strains similar to that of ETR.  Data from Phase 
IIA of a short-term monotherapy trial evaluating the antiviral activity, safety and 
pharmacokinetics of RDEA806 have demonstrated that this compound exerts a robust 
antiretroviral activity in HIV-1 positive, antiretroviral-naïve patients treated once daily for 7 
days. All doses of RDEA806 tested were well tolerated and no patient’s treatment was 
discontinued due to adverse effects (Moyle, 2010). 
2.5.3 IDX899 
This 3-phosphoindol compound also has a potent in vitro activity against wild-type and 
NNRTI-resistant strains of HIV-1, and possesses a high genetic barrier to resistance. 
Preliminary data from a Phase IIA trial of treatment-naïve patients undergoing 7 day 
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monotherapy with IDX899 suggest a potent antiviral activity and tolerability with all the 
doses evaluated (Klibanov, 2010). 
2.5.4 Lersivirine (UK-453061) 
This compound belongs to the pyrazole family and exhibits a good resistance profile in vitro. 
Results from a phase IIA clinical trial in which asymptomatic HIV-1 infected adults were 
treated once or twice daily with lersivirine in a 7-day monotherapy regimen demonstrate its 
high antiviral activity and good safety and tolerability profile. Nevertheless, some minor 
adverse effects (headache, fatigue and nausea) have been reported (Corbau, 2010; 
Fätkenheurer, 2009). 
3. NNRTI-associated adverse effects 
NVP and EFV, the most widely employed NNRTI, share a similar efficacy and genetic 
barrier against the development of drug resistance, but differ in their toxicological profiles. 
Clinical trials have generally shown NNRTI, and especially EFV, to be safe and well-
tolerated drugs. However, treatment discontinuation has been reported in patients receiving 
EFV- and NVP-based regimens, and is mainly attributed to the appearance of several 
moderate-to-severe side effects, some of which are drug-specific and unrelated to NNRTI as 
a pharmacological group. The most common adverse effects are cutaneous reactions, 
hepatotoxicity, neuro-psychiatric toxicity and metabolic alterations, but other toxicities have 
also been described to a lesser extent (Figure 3).  
Discontinuation rates of up to 16% have been reported in patients receiving EFV and two 
NRTI, and similar or higher levels have been found following treatment with NVP. For 
example, in a study comparing EFV and NVP (each in combination with Lamivudine (3TC) 
and Stavudine (d4T)), discontinuation was necessary in 15.8% and 24.1% of treatments with 
EFV and NVP respectively (van Leth, 2004). It is important to note that the incidence of 
discontinuation of EFV-based therapy also depends on the NRTI co-administered, being 
more frequent when EFV is used with 3TC and Zidovudine (AZT) or with 3TC and 
Abacavir (Bartlett, 2007). In the FIRST study, severe (grade 4) adverse events were 
approximately half as common with EFV as with NVP (van der Berg-Wolf, 2008), especially 
in the case of rash and hepatotoxicity. Nevertheless, NVP can be considered an alternative 
therapy when there is a high risk of central nervous system (CNS) toxicity because of its lack 
of association with neuropsychiatric events (Hawkins, 2005; van Leth, 2004). 
3.1 Cutaneous reactions 
All NNRTI have been associated with skin reactions, but they differ in the frequency and 
severity of the adverse events, with being rash one of the most common manifestations.  The 
majority of the cutaneous reactions associated NVP (including Stevens-Johnson syndrome, 
toxic epidermal necrolysis and hypersensitivity) appear within the first six weeks of 
treatment and can lead to therapy discontinuation if serious. Data from a metaanalysis 
revealed that 24% of NVP-treated patients suffered rash compared with 15% of controls, 
while 1.7% of patients showed severe grade 3 and 4 reactions vs 0.2% of controls [40]. One of 
the proposed mechanisms in NVP-mediated rash involves the 12-hydroxy metabolite of this 
drug, which can be converted to a reactive quinone methide in the skin, thus inducing an 
immune response and rash (Popovic, 2010).  
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Fig. 3. NNRTI-related adverse events  
Mild-to-moderate rash has also been described in patients receiving EFV-based regimens, 
and is usually resolved as therapy continues, although approximately 2% of patients 
discontinue their treatment. These reactions usually appear as maculopapular skin 
eruptions within the first two weeks of treatment, but less than 1% patients develop severe 
rash, characterised by blistering, moist desquamation or ulceration, and only 0.1% suffer 
grade 4 rash, manifested as erythema multiforme or Stevens-Johnson syndrome. In 
controlled trials, the incidence of skin reactions was 26% in patients treated with 600mg per 
day of EFV compared to 18% in controls (AIDSinfo, 2010). In the 2NN trial, the frequency of 
moderate-to-severe rash was significantly greater with NVP than EFV when both were 
administered once daily, but there was no significant difference between NVP twice daily 
and EFV once daily (van Leth, 2004).   
DLV and ETR have also been related to the onset of mild-to-moderate skin reactions. DLV-
induced rash usually appears within 1 to 3 weeks of treatment and is resolved in 3 to 14 days. 
In the DUET studies, the only significant side effect observed in the ETR group was rash, 
which was usually maculopapular and of mild-to-moderate severity (1.3% grade 3), occurred a 
median of 14 days after initiation of therapy, and lasted approximately 15 days. Severe rash 
was not reported, and only 2.2% of patients discontinued treatment due to this side effect.  
3.2 CNS toxicity  
EFV is widely associated with CNS toxicity, which is responsible for the discontinuation of 
treatment in at least 4-10% of patients (Muñoz-Moreno, 2009). Between 25 and 70% of 
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patients receiving EFV exhibit neuropsychiatric disturbances, including dizziness, headache, 
euphoria, hallucinations, impaired concentration, confusion, depersonalization, drowsiness, 
amnesia, sleep abnormalities (e.g. insomnia or vivid dreams), nervousness, anxiety and 
depression. More severe cases, consisting of depression, delusions, suicidal ideation and 
paranoid reactions, have been reported in 0.4 - 1.6% of EFV-treated patients (Staszewski, 
1999; Hawkins, 2005; Fumaz, 2002). These side effects usually appear within the first few 
days of treatment and are resolved after 2-4 weeks, although there are cases in which they 
continue to manifest themselves for several months or even longer periods (Muñoz-Moreno, 
2009; Arendt, 2007). The clinical evidence available, though extensive, is insufficient to 
clarify the mechanisms underlying EFV-induced CNS alterations, but recent data implicate 
neurotoxic events induced by HIV itself and cytokine production by EFV. 
These adverse effects in the CNS seem to be dose-related (Marzolini, 2001). For instance, the 
higher incidence of such events in Afro-Americans than in European-Americans or Hispanic 
populations is attributed to the greater prevalence of the CYP2B6 T/T genotype in the 
former population, which results in a slower EFV metabolism and, consequently, higher 
plasma drug concentrations (Haas, 2004).   
None of the remaining NNRTI has been associated with neuropsychiatric adverse effects. 
Moreover, switching from EFV to ETR produces an improvement in EFV-induced toxicity, 
with a significant reduction of CNS events such as insomnia, abnormal dreams and 
nervousness (Waters, 2011). 
3.3 Metabolic alterations 
Mounting evidence associates NNRTI with metabolic disorders involving lipid metabolism, 
such as alterations of body fat distribution (lipodystrophy) and dyslipidaemia (changes in 
plasma concentration of cholesterol, High Density Lipoprotein Cholesterol (HDL-c), Low 
Density Lipoprotein Cholesterol (LDL-c), triglycerides). Lipid alterations are sometimes 
accompanied by insulin resistance and can generate a metabolic syndrome-like condition. 
These effects seem to be drug-specific, but the mechanisms involved are still not fully 
understood. Increases in HDL-c have been reported in naïve patients treated with different 
NNRTI-based regimens (Negredo, 2004; van der Valk, 2001), but clinical studies have not 
clarified which drug(s) was/were responsible for these effects. 
There is conflicting evidence as to whether HDL-c is significantly altered in patients 
switched from a PI- to a NNRTI-based regimen (Martínez, 2000; Negredo, 2002). The lipid 
profile of naïve patients receiving NVP or EFV plus d4T and 3TC was evaluated in a pre-
planned study within the larger 2NN trial. NVP was associated with greater increases in 
HDL-c (42.5% with NVP vs 33.7% with EFV) and lower increases in total cholesterol (TC) 
levels (26.9% with NVP vs 31.1% with EFV), which led to a decrease in the TC:HDL-c ratio 
in patients receiving NVP (-4.1%). No significant differences were detected in LDL-c levels. 
Similarly, different dysmetabolic profiles were reported in a cross-sectional evaluation of 
EFV- and NVP-treated patients (Manfredi, 2005), with rates of hyperglycemia, 
hypertriglyceridemia and hypercholesterolemia being higher in the former group. The same 
report showed that, when patients were switched to NNRTI-containing therapies, 
dysmetabolism was ameliorated by NVP, whereas it was stabilised or worsened by EFV. In 
the case of DLV and ETR, neither has been significantly associated with lipid abnormalities. 
The cellular and molecular mechanisms underlying NNRTI-induced metabolic alterations 
are still unclear, and many hypotheses have emerged to explain them. Some in vitro studies 
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have suggested that EFV-induced lipodystrophy is a result of effects on adipocyte 
differentiation and function, whereas such effects are not observed with NVP. In particular, 
clinically relevant EFV concentrations have been shown to alter the lipogenic pathway of 
cell differentiation by preventing lipid storage in 3T3 or human preadipocytes and to 
deplete triacylglycerol accumulation in 3T3-F442A mature adipocytes. These phenomena, 
which were attributed to the reduction in the expression of the lipogenic transcription factor 
SREBP-1c, may be involved in the atrophy of adipose tissue described in HAART-treated 
patients (Diaz-Delfin, 2008; El-Hadri, 2004). When the effects of EFV and a boosted IP, 
lopinavir/ritonavir (LPV/r; 4:1), were compared in human adipocytes during and after 
adipogenic differentiation, both compounds were found to impair adipogenesis and reduce 
transcript levels of adipogenic differentiation genes and master regulators of adipogenesis. 
In addition, they undermined the release of adipokine and enhanced the expression and 
release of inflammation-related cytokines. All these effects were more pronounced with EFV 
than with LPV/r (Gallego-Escuredo, 2010). 
3.4 Hepatotoxicity 
Hepatic adverse events are one of the main causes of mortality and morbidity in HIV-
infected patients and are associated with the vast majority of antiretroviral drugs. Therefore, 
it is important to note that increased liver enzyme levels are a common feature of 
antiretroviral therapy (Palella, 2006; Weber, 2006). NNRTI , specially NVP and EFV, have 
been related to liver damage, but there is controversy regarding the level of toxicity of each 
compound and the relationship between NNRTI plasma levels and hepatotoxicity (Law, 
2003). However, it is accepted that the risk of this adverse effect is increased in patients in 
whom liver enzymes levels were elevated prior to therapy and/or are co-infected with 
hepatitis B (HBV) and/or C (HCV) (Brück, 2008; Sulkowski, 2002).  
Liver damage is particularly prevalent among NVP-treated patients, but most trials have not 
detected a positive correlation with the plasma concentration of this compound (Cooper, 
2007; Kappelhoff, 2005). Liver enzyme levels normally increase within the first 18 weeks of 
therapy, but the risk continues thereafter, and so patients should be monitored at frequent 
intervals throughout their treatment. Severe life-threatening hepatotoxicity, including fatal 
fulminant hepatitis, has also been reported during therapy with NVP. In a recent study of 
NVP patients, 25.7% developed grade 1 hepatotoxicity and 2.8% displayed severe 
hepatotoxicity (Jena, 2009). There is also conflicting evidence about the involvement of NVP 
therapy in the progression of liver fibrosis in patients with a concomitant HCV infection, as 
some studies support this hypothesis (Macías, 2004) whereas others relate NVP to a 
reduction of fibrosis (Berenguer, 2008).  
Up to 10% of EFV-treated patients exhibit increases of liver enzymes that may require  
discontinuation of therapy and which have been associated both with hypersensitivity to 
EFV and dose-dependent accumulative effects (Angel-Moreno-Maroto, 2006; Jena, 2009; 
Kappelhoff, 2005; Rivero, 2007). In fact, a substudy of the 2NN trial showed a correlation 
between the incidence of elevated levels of liver enzymes and plasma concentrations of EFV 
during the first 6 weeks of treatment. The risk of hepatotoxicity in EFV-treated patients 
increases considerably when HIV coexists with HBV and/or HCV infection (Ena, 2003; 
Sulkowski, 2002), and also when patients are treated with other potential hepatotoxic 
medicinal products. It has been claimed that hepatitis viral co-infection results in a higher 
exposure to EFV. In this context, there are studies that have failed to detect any differences 
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in plasma EFV concentrations between uninfected and HBV/HCV-infected patients 
(Katsounas, 2007; Pereira, 2008), while others report increased median plasma C(min) values 
leading to overdosing of NNRTI in HIV/HCV co-infected patients, especially in those at an 
advanced stage of liver fibrosis (Dominguez, 2010). Recent results from Phase III DUET 
trials have pointed to the good safety profile of ETR in patients co-infected with HIV and 
HBV and/or HCV, among whom the incidence and severity of hepatic adverse events were 
similar to those in the placebo group (Clotet, 2010). Finally, several cases of acute liver 
failure have been described with NVP and only a few with EFV, though this is a rarely 
reported hepatic event during antiretroviral therapy (Jao, 2010; Turkova, 2009).  
The cellular and molecular mechanisms underlying NNRTI-induced hepatotoxicity remain 
elusive, and there is little and contradictory information about the in vitro toxic effects of 
EFV on hepatic cells.  
3.5 Other toxicities 
Less common side effects have also been associated with NNRTI-including therapies. 
Moderate gastrointestinal adverse effects have been reported with all NNRTI,  but do not 
normally lead to the discontinuation of therapy. In general, NNRTI-related symptoms 
include nausea, diarrhoea, vomiting and abdominal pain, but EFV has also been associated 
with anorexia, dyspepsia and pancreatitis. These gastrointestinal EFV-associated adverse 
effects have been reported in up to 14% of patients, and increases in serum amylase 
concentration have been reported in 10% of patients receiving EFV compared to 6% of 
controls (AIDSinfo, 2010). 
Several in vitro and clinical studies have raised the possibility that EFV contribute to 
HAART-associated cardiovascular complications in HIV-infected patients. Treatment of 
human coronary artery endothelial cells (HCAEC) with EFV leads to increased oxidative 
stress, evident in the induction of superoxide production and decrease of GSH levels, which 
significantly increases the in vitro monolayer permeability of these cells (Jamaluddin, 2009). 
In the study in question, antioxidant administration demonstrated that EFV-induced ROS 
also activated several cellular pathways mediated by JNK and NFB and pointed to an 
involvement of this drug in inflammatory processes. Clinical evidence from a recent trial 
evaluating cardiovascular risk factors in patients treated for over 5 years with NVP- or EFV-
based regimens associate the former drug with a better lipid and glucose profile and a lower 
tendency to develop subclinical atherosclerotic lesions than the latter drug (Maggi, 2011). 
EFV therapy has recently been reported to induce vitamin D deficiency and elevated serum 
alkaline phosphatase levels, both of which are considered to be markers of bone toxicity and 
turnover (Welz, 2010). This compound has also been associated with significant decreases in 
25-hydroxyvitamin D and an increased risk of hypovitaminosis D (Brown, 2010). 
Preliminary studies in rats have suggested that high doses of EFV induce nephrotoxicity, 
expressed by necrosis of proximal tubular epithelial cells. Although humans are exposed to 
higher levels of EFV, this effect has not been corroborated in patients (Gerson, 1999; Mutlib, 
2000). Species selectivity with respect to this toxic effect may result from differences in the 
production and/or processing of reactive metabolites. Some EFV-treated patients have 
reported hyperhidrosis, which is manifested as excessive nocturnal sweating and could be a 
consequence of alterations of the body’s thermoregulation by high concentrations of this 
NNRTI in the cerebroespinal fluid. This adverse event can be controlled by dose reduction 
(Fuertes, 2009). 
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4. NNRTI-induced side effects: A potential role for mitochondria? 
The mechanism of mitochondria-related toxicity most commonly associated with 
antiretroviral therapy is the inhibition of the enzyme responsible for mitochondrial DNA 
replication: DNA polymerase  (Pol ) (Walker, 2002). This toxicity is particularly related to 
NRTI treatment, and not to other antiretroviral drugs considered safer for mitochondrial 
function. However, recent evidence demonstrates that NNRTI act on various mitochondrial 
parameters without affecting Pol , which suggests a role for this organelle in NNRTI-
induced toxicities (Pilon, 2002; Karamchand, 2008). Nevertheless, the identification of a 
specific clinical profile related to mitochondrial toxicity is challenged by the co-
administration of these compounds with NRTI. Recent research has focused on the 
molecular and cellular mechanisms underlying NNRTI-associated adverse events, and on 
the potential role of mitochondria in such processes. Studies in endothelial cells have 
confirmed that EFV treatment induces ROS production and decreases GSH levels, 
contributing to endothelial dysfunction, an early stage of atherosclerosis (Jamaluddin, 2010). 
Additionally, EFV has been shown to induce mitochondrial apoptosis in Jurkat T cells and 
human peripheral blood mononuclear cells (Pilon, 2002). In this regard, we have recently 
characterized specific features of both EFV- and NVP-associated toxicity that are related to 
the induction of hepatic damage (Apostolova, 2010; Blas-García, 2010). In particular, we 
have reported evidence of a new mechanism of mitochondrial interference induced by EFV 
in human hepatic cells and which does not involve an effect on mitochondrial DNA 
replication. EFV decreased mitochondrial oxygen consumption by a direct inhibition of 
Complex I at the electron transport chain, and induced a reduction of mitochondrial 
membrane potential and an increase in reactive oxygen species (ROS) generation. The 
impairment of oxidative phosphorylation led to a reduction in cellular ATP levels and a 
subsequent activation of AMP-activated protein kinase (AMPK), which is the cellular master 
switch of energetic stress (Hardie, 2007). Indeed, the mitochondrial dysfunction observed 
produced alterations in lipid metabolism, increasing the lipid content in the cytoplasm in an 
AMPK-related fashion. These changes were accompanied by a relative increase in 
mitochondrial mass, without an increase in the mtDNA/nuclear DNA copy number ratio, 
which points to a lack of authentic mitochondrial biogenesis. EFV also compromised cellular 
viability and proliferation in both Hep3B and HeLa cells. Specifically, EFV led to cell cycle 
arrest and induced apoptotic cell death through the intrinsic (mitochondrial) pathway, 
which was evident in the translocation of mitochondrial apoptogenic proteins (cytochrome c 
and AIF), activation of caspase-3 and -9 and apoptotic changes in the nuclear morphology, 
such as chromatin condensation. EFV-induced toxic effects on cellular viability and 
proliferation were attenuated by an antioxidant treatment with the hydrosoluble analog of 
vitamin E, Trolox, thus implicating oxidative stress in these processes (Figure 4). 
Interestingly, NVP had no effect on the mitochondrial parameters analysed, but did produce 
a toxic effect on cellular viability and proliferation. In light of these findings, it is plausible 
that the deleterious mitochondrial effect induced by EFV is relevant to the development not 
only of hepatotoxicity but also to some of the more systemic metabolic side effects 
associated with this drug. These results are a strong endorsement of clinical evidence that 
the mechanisms of hepatotoxicity induced by NVP and EFV are drug-specific and unrelated 
to NNRTI as a drug family. 
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Fig. 4. Schematic representation of the direct mitotoxic effect induced by efavirenz (EFV) in 
hepatic cells in vitro.  
5. Conclusions 
Twenty years after the identification of NNRTI as a new class of antiretroviral drugs for the 
treatment of HIV-1 infection, recent advances in the characterization of the causes of their 
toxicity and the development of new compounds have put NNRTI in the spotlight. Given 
that these compounds are essential elements of antiretroviral therapy, the characterization of 
their toxic effects and the mechanisms that underlie them may help to improve HIV therapy. 
The real impact of newly developed compounds on HAART remains to be seen, but they are 
likely to play an important role in future antiretroviral regimens. Finally, the fact that HIV is 
now a chronic illness means that therapy must be administered for life; therefore, the choice 
of drugs to be taken should be based not only on their clinical efficacy but also on their 
toxicological profile, bearing in mind their profound influence on other concomitant 
infections and age-related diseases. 
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